Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract (NCT05191706)
A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
🩺 Plain-English Summary (8th-Grade Level)
A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCUfor the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
Who can join: Review the eligibility criteria below.
Location: EyePoint Investigational Site — Huntington Beach, California
Age range: Not specified to 3 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- EyePoint Investigational Site — Huntington Beach, California
- EyePoint Investigational Site — Palo Alto, California
- EyePoint Investigative Site — Boston, Massachusetts
- EyePoint Investigational Site — Jackson, Mississippi
- EyePoint Investigational Site — Omaha, Nebraska
- EyePoint Investigational Site — Buffalo, New York
- EyePoint Investigative Site — New York, New York
- EyePoint Investigational Site — Rochester, New York
- EyePoint Investigational Site — Charleston, South Carolina
📞 Contact the Study Coordinator
Phone: (833) 393-7646
Email: rribeiro@eyepointpharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cataract
- Clinical Study of a Fluid Accommodating Intraocular Lens (IOL) Design — San José,
- Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution — Glendale, Arizona
- Impact of a Novel Extended Depth of Focus Intraocular Lens on Visual and Lifestyle Enhancement — Babylon, New York
- A Prospective, Single-Arm Clinical Evaluation of Visual, Refractive, and Patient-Reported Outcomes Following Bilateral Implantation of the TECNIS PureSee™ Extended Depth of Focus Intraocular Lens — Sioux Falls, South Dakota
- Visual Acuity Outcome Differences Between the Alcon Vivity Toric IOL and RxSight LAL+ — Bradenton, Florida
- Visual Outcomes of Tecnis Symfony Opti-Blue EDOF Intraocular Lens (IOL) — Greenwich, Connecticut
Explore by condition: All Cataract clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.